Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $356.80 | 6 | 89.1% |
| Education | $43.44 | 3 | 10.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $157.70 | 4 | $0 (2023) |
| Gilead Sciences Inc | $126.30 | 3 | $0 (2017) |
| La Jolla Pharmaceutical Company | $96.37 | 1 | $0 (2023) |
| Alkermes, Inc. | $19.87 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $232.33 | 4 | Merck Sharp & Dohme LLC ($135.96) |
| 2022 | $21.74 | 1 | Merck Sharp & Dohme LLC ($21.74) |
| 2021 | $19.87 | 1 | Alkermes, Inc. ($19.87) |
| 2017 | $126.30 | 3 | Gilead Sciences Inc ($126.30) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/04/2023 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $96.37 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 09/22/2023 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Education | In-kind items and services | $10.85 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/27/2023 | Merck Sharp & Dohme LLC | ZINPLAVA (Biological) | Education | In-kind items and services | $10.85 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/22/2023 | Merck Sharp & Dohme LLC | RECARBRIO (Drug) | Food and Beverage | In-kind items and services | $114.26 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/20/2022 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Education | In-kind items and services | $21.74 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/28/2021 | Alkermes, Inc. | VIVITROL (Drug) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: CNS | ||||||
| 06/30/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $20.17 | General |
| 04/19/2017 | Gilead Sciences Inc | Genvoya (Drug) | Food and Beverage | In-kind items and services | $83.34 | General |
| Category: HIV | ||||||
| 01/19/2017 | Gilead Sciences Inc | Harvoni (Drug) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: HCV | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 707 | 1,437 | $552,874 | $154,219 |
| 2022 | 5 | 471 | 978 | $317,403 | $87,408 |
| 2021 | 2 | 57 | 123 | $16,275 | $8,405 |
| 2020 | 2 | 53 | 108 | $14,300 | $7,346 |
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 347 | 989 | $338,238 | $103,689 | 30.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 197 | 208 | $137,904 | $30,993 | 22.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 96 | 131 | $31,047 | $9,049 | 29.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 46 | 76 | $34,960 | $7,956 | 22.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 21 | 33 | $10,725 | $2,532 | 23.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 169 | 449 | $148,381 | $40,335 | 27.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 173 | 391 | $84,267 | $24,300 | 28.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 104 | 109 | $69,315 | $18,746 | 27.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 14 | 17 | $7,820 | $2,027 | 25.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 12 | $7,620 | $2,000 | 26.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 44 | 105 | $13,125 | $6,743 | 51.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 13 | 18 | $3,150 | $1,662 | 52.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 41 | 92 | $11,500 | $5,838 | 50.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 16 | $2,800 | $1,508 | 53.8% |
About Dr. Szilvia Molitorisz, MD
Dr. Szilvia Molitorisz, MD is a Internal Medicine healthcare provider based in Walnut Creek, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1295806289.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Szilvia Molitorisz, MD has received a total of $400.24 in payments from pharmaceutical and medical device companies, with $232.33 received in 2023. These payments were reported across 9 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($356.80).
As a Medicare-enrolled provider, Molitorisz has provided services to 1,288 Medicare beneficiaries, totaling 2,646 services with total Medicare billing of $257,379. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease
- Location Walnut Creek, CA
- Active Since 11/13/2006
- Last Updated 03/03/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1295806289
Products in Payments
- RECARBRIO (Drug) $114.26
- XERAVA (Drug) $96.37
- Genvoya (Drug) $83.34
- ZERBAXA (Drug) $32.59
- Harvoni (Drug) $22.79
- VIVITROL (Drug) $19.87
- ZINPLAVA (Biological) $10.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Walnut Creek
Anthony Padula, M.d, M.D
Internal Medicine — Payments: $804,141
Dr. Richard Chang, M.d, M.D
Internal Medicine — Payments: $295,804
Dr. Neal White, Md, MD
Internal Medicine — Payments: $224,225
Dr. Aditi Choudhry, M.d, M.D
Internal Medicine — Payments: $69,819
Dr. Andrew Dublin, Md, MD
Internal Medicine — Payments: $65,190
Dr. Bhavna Malik, Md, MD
Internal Medicine — Payments: $39,855